| Autor: |
Marcus Vinicius Branco de Oliveira, Sergio Irikura, Fabiani Honorato de Barros Lourenço, Monica Shinsato, Tereza Cristina Duarte Batista Irikura, Rodrigo Batista Irikura, Tales Vieira Cavalvanti Albuquerque, Vilma Neri Shinsato, Vinicius Nakad Orsatti, Antônio Mendes Fontanelli, Danyelle Amélia Grecco Samegima, Marcus Vinícius Magno Gonçalves, Daniel Galera Bernabé |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Brain, Behavior, & Immunity - Health, Vol 14, Iss , Pp 100252- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3546 |
| DOI: |
10.1016/j.bbih.2021.100252 |
| Popis: |
Encephalopathy is one of the most frequent neurological complications of severe Coronavirus Disease 2019 (COVID-19) patients. Cytokine storm and sepsis, hypercatabolic states, the use of furosemide and dialytic therapy represent risk factors for thiamine deficiency and are also found in patients with severe COVID-19. In this retrospective case series, we report clinical and neurological findings of fifteen patients with COVID-19-associated Wernicke Encephalopathy (WE) and their response to treatment with intravenous thiamine. All patients had encephalopathy, with 67% displaying at least one additional sign of classic WE triad (ophthalmoparesis and ataxia). Two patients (13%) had the classic triad. All COVID-19 patients had significant improvement of the neurological manifestations between two to five days after intravenous thiamine administration. Eleven patients (73%) had good neurological outcome at hospital discharge and only two patients (13%) died. This case series suggests that thiamine deficiency may be an etiology of encephalopathy in severe COVID-19 patients and its treatment may represent a safety and low-cost response to reduce the neurological burden. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
